Exelixis (NASDAQ:EXEL) insider Michael Morrissey sold 90,000 shares of the stock in a transaction that occurred on Wednesday, April 11th. The stock was sold at an average price of $20.78, for a total value of $1,870,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
NASDAQ EXEL opened at $20.87 on Friday. Exelixis has a 1-year low of $18.03 and a 1-year high of $32.50. The company has a market capitalization of $6,191.27, a P/E ratio of 40.92 and a beta of 2.10.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, February 26th. The biotechnology company reported $0.12 earnings per share for the quarter, meeting the consensus estimate of $0.12. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The firm had revenue of $120.10 million during the quarter, compared to the consensus estimate of $120.25 million. During the same period last year, the business posted $0.12 EPS. Exelixis’s quarterly revenue was up 54.8% on a year-over-year basis. equities analysts predict that Exelixis will post 0.58 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EXEL. American Century Companies Inc. increased its stake in Exelixis by 426.4% in the 4th quarter. American Century Companies Inc. now owns 1,469,945 shares of the biotechnology company’s stock valued at $44,686,000 after purchasing an additional 1,190,691 shares in the last quarter. Jennison Associates LLC increased its stake in Exelixis by 38.1% in the 4th quarter. Jennison Associates LLC now owns 4,228,761 shares of the biotechnology company’s stock valued at $128,554,000 after purchasing an additional 1,167,758 shares in the last quarter. Smith Asset Management Group LP purchased a new position in Exelixis during the fourth quarter worth $26,323,000. Caisse DE Depot ET Placement DU Quebec purchased a new position in Exelixis during the fourth quarter worth $17,480,000. Finally, Arrowstreet Capital Limited Partnership increased its position in Exelixis by 34.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,843,129 shares of the biotechnology company’s stock worth $56,031,000 after buying an additional 471,023 shares in the last quarter. 80.49% of the stock is owned by hedge funds and other institutional investors.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.